CLINICAL RESEARCH: HEART FAILURE
Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart Failure
Aidan P. Bolger, BSc, MRCP*,*,
Frederick R. Bartlett, MBBS ,
Helen S. Penston, SRN,
Justin O’Leary, BSc, DMU*,
Noel Pollock, MBBS,
Raffi Kaprielian, MD, MRCP and
Callum M. Chapman, MRCP
* Department of Clinical Cardiology, The Heart Hospital, London, United Kingdom
Clinical Heart Failure Service, West Middlesex University Hospital, Isleworth, United Kingdom.
Manuscript received April 10, 2006;
revised manuscript received July 7, 2006,
accepted July 10, 2006.
* Reprint requests and correspondence: Dr. Aidan P. Bolger, Department of Adult Cardiology, The Heart Hospital, 16-18 Westmoreland Street, London W1G 8PH, United Kingdom. (Email: aidan{at}bolgers.org).
OBJECTIVES: This study was undertaken to assess the hematologic, clinical, and biochemical response to intravenous iron in patients with chronic heart failure (CHF) and anemia.
BACKGROUND: Anemia is common in patients with CHF and is associated with higher morbidity and mortality. The combination of erythropoietin (EPO) and iron increases hemoglobin (Hb) and improves symptoms and exercise capacity in anemic CHF patients. It is not known whether intravenous iron alone is an effective treatment for anemia associated with CHF.
METHODS: Sixteen anemic patients (Hb  12 g/dl) with stable CHF (age 68.3 ± 11.5 years, 12 men, 9 participants New York Heart Association [NYHA] functional class II and the remainder class III, left ventricular ejection fraction 26 ± 13%) received a maximum of 1 g of iron sucrose by bolus intravenous injections over a 12-day treatment phase in an outpatient setting. Mean follow-up was 92 ± 6 days.
RESULTS: Hemoglobin rose from 11.2 ± 0.7 to 12.6 ± 1.2 g/dl (p = 0.0007), Minnesota Living with Heart Failure (MLHF) score fell (denoting improvement) from 33 ± 19 to 19 ± 14 (p = 0.02), 6-min walk distance increased from 242 ± 78 m to 286 ± 72 m (p = 0.01), and all patients recorded NYHA class II at study end (p < 0.02). Changes in MLHF score and 6-min walk distance related closely to changes in Hb (r = 0.76, p = 0.002; r = 0.56, p = 0.03, respectively). Of all baseline measurements, only iron and transferrin saturation correlated with increases in Hb (r = 0.60, p = 0.02; r = 0.60, p = 0.01, respectively). There were no adverse events relating to drug administration or during follow-up.
CONCLUSIONS: Intravenous iron sucrose, when used without concomitant EPO, is a simple and safe therapy that increases Hb, reduces symptoms, and improves exercise capacity in anemic patients with CHF. Further assessment of its efficacy should be made in a multicenter, randomized, placebo-controlled trial.
|
Abbreviations and Acronyms
| | CHF = chronic heart failure | | EPO = erythropoietin | | Hb = hemoglobin | | GI = gastrointestinal | | MLHF = Minnesota Living with Heart Failure | | NYHA = New York Heart Association | | 6MW = 6-min walk |
|
This article has been cited by other articles:
|
|
|
|
 
S. D. Anker, J. Comin Colet, G. Filippatos, R. Willenheimer, K. Dickstein, H. Drexler, T. F. Luscher, B. Bart, W. Banasiak, J. Niegowska, et al.
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
N. Engl. J. Med.,
November 17, 2009;
(2009)
NEJMoa0908355v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Anker, J. C. Colet, G. Filippatos, R. Willenheimer, K. Dickstein, H. Drexler, T. F. Luscher, C. Mori, B. von Eisenhart Rothe, S. Pocock, et al.
Rationale and design of Ferinject(R) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia
Eur J Heart Fail,
November 1, 2009;
11(11):
1084 - 1091.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Besarab, W. H. Horl, and D. Silverberg
Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome
Oncologist,
September 1, 2009;
14(suppl_1):
22 - 33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kazory and E. A. Ross
Anemia: the point of convergence or divergence for kidney disease and heart failure?
J. Am. Coll. Cardiol.,
February 24, 2009;
53(8):
639 - 647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. D. Pagourelias, C. Koumaras, A. I. Kakafika, K. Tziomalos, P. G. Zorou, V. G. Athyros, and A. Karagiannis
Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure?
Angiology,
February 1, 2009;
60(1):
74 - 81.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. S. Silverberg, D. Wexler, A. Iaina, and D. Schwartz
The Role of Correction of Anemia in Patients With Congestive Heart Failure Associated with Chronic Kidney Failure
Journal of Pharmacy Practice,
December 1, 2008;
21(6):
420 - 423.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Adlbrecht, S. Kommata, M. Hulsmann, T. Szekeres, C. Bieglmayer, G. Strunk, G. Karanikas, R. Berger, D. Mortl, K. Kletter, et al.
Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume
Eur. Heart J.,
October 1, 2008;
29(19):
2343 - 2350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Silverberg, D. Wexlerb, A. Iaina, and D. Schwartz
The role of correction of anaemia in patients with congestive heart failure: A short review
Eur J Heart Fail,
September 1, 2008;
10(9):
819 - 823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Anand
Anemia and Chronic Heart Failure: Implications and Treatment Options
J. Am. Coll. Cardiol.,
August 12, 2008;
52(7):
501 - 511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. C. Levy
Anemia in heart failure: marker or mediator of adverse prognosis?
J. Am. Coll. Cardiol.,
February 5, 2008;
51(5):
577 - 578.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O. Okonko, A. Grzeslo, T. Witkowski, A. K.J. Mandal, R. M. Slater, M. Roughton, G. Foldes, T. Thum, J. Majda, W. Banasiak, et al.
Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency: FERRIC-HF: A Randomized, Controlled, Observer-Blinded Trial
J. Am. Coll. Cardiol.,
January 15, 2008;
51(2):
103 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Toblli, A. Lombrana, P. Duarte, and F. Di Gennaro
Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency
J. Am. Coll. Cardiol.,
October 23, 2007;
50(17):
1657 - 1665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Francis and A. Kanderian
Anemia and Heart Failure: A New Pathway?
J. Am. Coll. Cardiol.,
October 23, 2007;
50(17):
1666 - 1667.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. F. Murphy and K. McDonald
Treatment of anaemia in chronic heart failure optimal approach still unclear
Eur. Heart J.,
September 2, 2007;
28(18):
2185 - 2187.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Nanas, C. Matsouka, and M. I. Anastasiou-Nana
Reply
J. Am. Coll. Cardiol.,
June 12, 2007;
49(23):
2302 - 2302.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. van Veldhuisen, J. J.V. McMurray, and RED-HF Executive Committee
Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial
Eur J Heart Fail,
February 1, 2007;
9(2):
110 - 112.
[Full Text]
[PDF]
|
|
|
|
